Public Comments - Revised Interim Guidelines for Examination

Public Comments on the United States Patent and Trademark Office
"Revised Interim Guidelines for Examination of Patent Applications
Under the 35 U.S.C. § 112, ¶1 ‘Written Description’ Requirement"
64 FR 71427, Dec. 21, 1999

NOTE: Comments submitted in electronic form were reformatted for margin and font consistency. Comments submitted on paper were scanned. Comments were listed alphabetically by individuals and then by organizations. Comments that addressed both the Utility and the Written Description Guidelines have been reproduced in both comment packages.
Comment 1 Cristina Azevedo
Comment 2 Karen S. Bentley
Comment 3 Philip L. Bereano
Comment 4 Alder S. Bourinbaiar
Comment 5 Elizabeth Bravo
Comment 6 Richard Broome
Comment 7 Don Burgett
Comment 8 W. Robinson H. Clark et al.
Comment 9 Liberty Coates
Comment 10 Gary Colby
Comment 11 Iver Cooper
Comment 12 George Corey
Comment 13 Deirdre Cummings
Comment 14 Jill Davies
Comment 15 Stanislaus J. Dundon
Comment 16 Samuel S. Epstein
Comment 17 Paul Fehlner
Comment 18 Laurie Ferreri
Comment 19 Thomas G. Field, Jr.
Comment 20 Bill Freese
Comment 21 Barry Hindmarch
Comment 22 Helen Jones
Comment 23 Gary Kah
Comment 24 Jonathan King
Comment 25 Christian Lacoste
Comment 26 Herbert Lass
Comment 27 Rod Leonard
Comment 28 Glenda Lindsay
Comment 29 Ann Lindsey
Comment 30
Comment 31 Ed Muniak
Comment 32 Nell Newman
Comment 33 Frances Oliver
Comment 34 Steve Openshaw
Comment 35 Valerie J. Phillips
Comment 36 Harris A. Pitlick
Comment 37 Mora Rogers
Comment 38 Kate Savannah
Comment 39 Donald Sawyer
Comment 40 Belia Schuurman
Comment 41 Andrew Taynton
Comment 42 Jesus Juanos i Timoneda
Comment 43 John O. Tresansky
Comment 44 Carlos A. Vicente
Comment 45 Sally Whelan
Comment 46 Kelley Wiley
Comment 47 Mary Wiley
Comment 48 Warren D. Woessner
Comment 49 American Bar Association, Section of Intellectual Property Law/ Gregory J. Maier
Comment 50 American College of Medical Genetics/ R. Rodney Howell
Comment 51 American Intellectual Property Law Association/ Louis T. Pirkey
Comment 52 American Society of Human Genetics/ Ronald Worton
Comment 53 Association of American Medical Colleges/ Jordan J. Cohen
Comment 54 BioIndustry Association / Andrew G. Sheard
Comment 55 Biotechnology Industry Organization / Charles E. Ludlam
Comment 56 Boston Women's Health Book Collective / Anna M. Pohl
Comment 57 Council for Responsible Genetics / Claire Nader
Comment 58 Eli Lilly and Co. / Amy E. Hamilton
Comment 59 Genentech, Inc. / Sean A. Johnston
Comment 60 Genzyme Corporation / Steve Lazar
Comment 61 MJ Research, Incorporated / Michael Finney
Comment 62 National Association of Patent Practitioners / Joy Bryant
Comment 63 National Breast Cancer Coalition / Fran Visco
Comment 64 National Institutes of Health / Jack Spiegel
Comment 65 National Organization for Rare Disorders, Inc. / Abbey S. Meyers
Comment 66 Physicians and Scientists for Responsible Genetics, New Zealand / Jean Anderson

Some contents linked to on this page require a plug-in for PDF file.